These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 1485465

  • 1. Guidelines for therapeutic studies on peripheral arterial occlusive disease in Fontaine stages II-IV. German society of Angiology.
    Heidrich H, Allenberg J, Cachovan M, Creutzig A, Diehm C, Gruss J, Kriessmann A, Rieger H, Rudofsky G, Trampisch HJ.
    Vasa; 1992; 21(4):333-43. PubMed ID: 1485465
    [No Abstract] [Full Text] [Related]

  • 2. [Bencyclane in stage II arterial occlusive disease. Results of a controlled study].
    Trübestein G, Trübestein R, Ludwig M.
    Fortschr Med; 1989 Dec 20; 107(36):781-4. PubMed ID: 2695437
    [Abstract] [Full Text] [Related]

  • 3. Guidelines for therapeutic studies in Fontaine's stages II-IV peripheral arterial occlusive disease. German Society of Angiology.
    Heidrich H, Cachovan M, Creutzig A, Rieger H, Trampisch HJ.
    Vasa; 1995 Dec 20; 24(2):107-19. PubMed ID: 7793141
    [No Abstract] [Full Text] [Related]

  • 4. [New data on vasoactive drug. Patients with peripheral arterial occlusive disease walk twice as long].
    MMW Fortschr Med; 2002 May 23; 144(21):54. PubMed ID: 12134429
    [No Abstract] [Full Text] [Related]

  • 5. [Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification].
    Branchereau A, Rouffy J.
    J Mal Vasc; 1995 May 23; 20(1):21-7. PubMed ID: 7745355
    [Abstract] [Full Text] [Related]

  • 6. [Vasoactive agents and prostanoids in the therapy of PAD: facts, questions, disproven assumptions].
    Heidrich H.
    Hamostaseologie; 2006 Aug 23; 26(3):220-3. PubMed ID: 16906239
    [Abstract] [Full Text] [Related]

  • 7. [Ifenprodil tartrate in the treatment of occlusive arteriopathies of the lower limbs. Results of a prospective double-blind controlled multicenter trial].
    Natali J, Kieny R, Le Bas P, Benhamou M, Molkhou JM.
    Ann Cardiol Angeiol (Paris); 1989 Jun 23; 38(6):339-42. PubMed ID: 2667444
    [No Abstract] [Full Text] [Related]

  • 8. [Effectiveness of buflomedil in arterial occlusive disease. Modification of transcutaneous oxygen pressure in a placebo-controlled double-blind study].
    Sunder-Plassmann L, Gandolfo AM, Utz C.
    MMW Munch Med Wochenschr; 1984 Mar 02; 126(9):247-8. PubMed ID: 6425678
    [No Abstract] [Full Text] [Related]

  • 9. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group.
    Beischer W, Dembski JC, Gruss JD, Hofgärtner F, Horsch A, Horsch S, Kuhlmann HW, Loose DA, Mietaschk A, Schwilden ED, Spengel F, Spitzer W, Staben P, Stallkamp B, Stürzebecher CS, Tokhi M, von Bilderling P.
    Vasa; 1998 Feb 02; 27(1):15-9. PubMed ID: 9540427
    [Abstract] [Full Text] [Related]

  • 10. [Intra-arterial drug therapy in arterial obstructions of the leg: value of high concentrations in the ischemic zones].
    Jorns G.
    Phlebologie; 1979 Feb 02; 32(1):43-6. PubMed ID: 432288
    [No Abstract] [Full Text] [Related]

  • 11. [Assessment of the clinical effectiveness of actihaemyl in Fontaine stage IIb intermittent claudication].
    Horsch S, Claeys L, Diehm C, Rieger H, Cachovan M, Baitsch C.
    Vasa Suppl; 1992 Feb 02; 37():64-5. PubMed ID: 1481105
    [No Abstract] [Full Text] [Related]

  • 12. [Experiences with solcoseryl in treatment of stage II peripheral arterial occlusive disease--assessment of clinical effectiveness].
    Horsch S, Claeys L.
    Vasa Suppl; 1992 Feb 02; 35():151-2. PubMed ID: 1481024
    [No Abstract] [Full Text] [Related]

  • 13. [Methodologic aspects of retrograde venous perfusion].
    Scheffler A, Friedrichs EA, Rieger H.
    Vasa Suppl; 1991 Feb 02; 32():422-4. PubMed ID: 1771549
    [No Abstract] [Full Text] [Related]

  • 14. [Transcutaneous measures of oxygen partial pressure and capillaroscopic parameters as affected by naftidrofuryl in patients with obliterative arteriopathies, Fontaine stages II-IV].
    Ranft J, Heidrich H, Lammersen T.
    J Mal Vasc; 1987 Feb 02; 12(1):78-81. PubMed ID: 3559415
    [Abstract] [Full Text] [Related]

  • 15. [Double-blind study of naftidrofuryl-hydrogen oxalate in peripheral arterial occlusive disease].
    Pohle W, Hirche H, Barmeyer J, Schümichen C, Hoffmann G.
    Med Welt; 1979 Feb 16; 30(7):269-72. PubMed ID: 372733
    [No Abstract] [Full Text] [Related]

  • 16. [Therapeutic use of flunarizine in the treatment arteriopathies of the lower extremities].
    Ambrosi V, Gabrielli F.
    Minerva Med; 1983 Mar 31; 74(13):685-9. PubMed ID: 6220230
    [Abstract] [Full Text] [Related]

  • 17. [Guidelines for the evaluation of the therapeutic effects of peripheral vasoactive drugs in arterial occlusive disease].
    Adank K, Barras JP, Biland L, Bollinger A, Galeazzi R, Kämpf R, Mirimanoff P, Schelling JL, Widmer LK.
    Vasa; 1981 Mar 31; 10(4):337-41. PubMed ID: 7032111
    [No Abstract] [Full Text] [Related]

  • 18. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
    Weiss T, Griesshaber J, Rogatti W, Kistner O, Hsu E, Jansen T, Diehm C.
    Vasa Suppl; 1991 Mar 31; 33():341-2. PubMed ID: 1788749
    [Abstract] [Full Text] [Related]

  • 19. [Double blind clinical experiences with L.S. 121 (praxilene) in patients with chronic ischemic peripheral syndromes].
    Bianchi G.
    Minerva Chir; 1974 Aug 15; 29(15-16):885-90. PubMed ID: 4607675
    [No Abstract] [Full Text] [Related]

  • 20. [Placebo controlled study of the effect of intravenous PGE1 on macro- and microcirculation in patients with stage III/IV arterial occlusive disease].
    Scheffler P, de la Hamette D, Leipnitz G.
    Vasa Suppl; 1991 Aug 15; 33():343-4. PubMed ID: 1788750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.